EverGlade in the Media
Featured On
Effect of Fiscal Responsibility Act on Project Next Gen BARDA Funding
The Fiscal Responsibility Act of 2023 aims to reduce USG spending by $2.1 trillion, with an additional $1.5 trillion in mandated savings over the next two years. The bill reclaims $28 billion of unutilized COVID-19 funds and cuts an additional $400 million from the CDC’s “Global Health Fund,” which channels taxpayer funds to China. Collectively, these cuts represent the largest rollback of federal spending in American history.
Amendment to BAA Outlines New BARDA Funding Opportunities for Next-generation COVID-19 Vaccines, Monoclonal Antibodies, and Antivirals
In the latest amendment to its Broad Agency Announcement (BAA), BARDA (Biomedical Advanced Research and Development Authority) is seeking proposals for the development of cost-effective and adaptable therapeutic platforms to treat viral infections, as well as next-generation COVID-19 vaccines.
EverGlade Funding Alert: CHIPS Act Funding Opportunity for Tech Hubs Program
The United States Economic Development Administration (EDA) released a Notice of Funding Opportunity (NOFO) for Regional Technology and Innovation Hubs (Tech Hubs). This initiative aims to foster innovation, collaboration, and economic growth by establishing regional technology hubs across the nation by providing funding and resources to create and expand technology-focused hubs.
EverGlade Assists Appili Therapeutics in Successful Pursuit of DTRA Funding
EverGlade (“EverGlade”), a national consulting firm, has helped Appili Therapeutics USA Inc. (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, secure an initial contract with the U.S. Air Force Academy (USAFA). USAFA is the prime contractor to DTRA for this program.
EverGlade Funding Alert: Biden Administration Announces Launch of Successor Program to Operation Warp Speed
CHARLESTON, S.C., April 12, 2023 /PRNewswire/ — Project Next Gen is a new program launched by the Biden administration aimed at accelerating the development of new coronavirus vaccines and treatments.
EverGlade: CHIPS for America Launches First Funding Opportunity (Commercial Fabrication Facilities)
The US Department of Commerce has opened the application process for companies to revitalize the domestic semiconductor industrial base. The move is aimed at securing a share of the multi-billion-dollar semiconductor opportunity by 2030 and strengthening leadership in chip manufacturing.
EverGlade Founder, Eric Jia-Sobota, Announces Promotions, New Hires and 20% Growth in Q12023
EverGlade (“EverGlade”), a national consulting firm, announces key promotions and new hires while achieving 20% growth in the first quarter of 2023.
EverGlade Helps Sabin Vaccine Institute Secure up to $214 Million in BARDA Funding to Develop and Procure Ebola Sudan and Marburg Vaccines
Prepaire Appoints Everglade Consulting to Secure Non-Dilutive Federal Government Funding for Multiple Projects
Prepaire Labs, an AI-driven biotechnology company powering drug discovery, repurposing, designing, and development, today announced the appointment of Everglade Consulting, a national consulting firm assisting biotechnology companies to secure non-dilutive federal funding.
EverGlade Helps Land up to $1 Billion in BARDA Funding for Biotechnology Company
EverGlade has helped a leading biotechnology company land an award from the Biomedical Advanced Research and Development Authority (BARDA) with a potential $1 billion in federal funding.
EverGlade Launches DOE Loan and CHIPS Support Practices
EverGlade (“EverGlade”), a national consulting firm, with employees in locations across the country, has launched two new practices to support recent legislation. EverGlade has been on the forefront of U.S. Government (“USG”) efforts to broaden the nation’s domestic industrial base to accommodate the manufacturing of critical supplies and materials.